Incyte Co. (NASDAQ:INCY) EVP Sheila A. Denton Sells 14,069 Shares


Incyte Co. (NASDAQ:INCY) EVP Sheila A. Denton Sells 14,069 Shares

Incyte Co. (NASDAQ:INCY - Get Free Report) EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares of the company's stock, valued at $1,914,561.36. This trade represents a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ INCY traded up $0.32 during trading hours on Friday, reaching $73.50. The company's stock had a trading volume of 1,489,085 shares, compared to its average volume of 1,608,318. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company's 50-day moving average is $71.68 and its two-hundred day moving average is $69.75. The firm has a market capitalization of $14.22 billion, a price-to-earnings ratio of 272.23, a P/E/G ratio of 0.41 and a beta of 0.70.

Incyte (NASDAQ:INCY - Get Free Report) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts predict that Incyte Co. will post 4.86 EPS for the current year.

A number of brokerages have recently weighed in on INCY. Royal Bank of Canada dropped their price objective on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company boosted their price target on Incyte from $68.00 to $70.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. JMP Securities restated a "market perform" rating on shares of Incyte in a research note on Tuesday, February 11th. Stifel Nicolaus upped their target price on Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, February 10th. Finally, William Blair reissued an "outperform" rating on shares of Incyte in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Incyte currently has a consensus rating of "Hold" and an average target price of $75.25.

Check Out Our Latest Analysis on Incyte

Several institutional investors have recently modified their holdings of the stock. CWA Asset Management Group LLC acquired a new stake in Incyte in the 4th quarter worth about $1,933,000. Orion Portfolio Solutions LLC acquired a new stake in shares of Incyte in the third quarter worth approximately $770,000. Greenwood Capital Associates LLC acquired a new stake in shares of Incyte in the third quarter worth approximately $433,000. Tri Ri Asset Management Corp purchased a new stake in shares of Incyte during the third quarter worth approximately $3,292,000. Finally, Cypress Capital Group acquired a new position in Incyte in the 3rd quarter valued at $971,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Incyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.

While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

Previous articleNext article

POPULAR CATEGORY

corporate

12286

tech

11464

entertainment

15252

research

7035

misc

16117

wellness

12376

athletics

16146